A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen.

@article{Poujol2007ALS,
  title={A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen.},
  author={Sylvain Poujol and Fr{\'e}d{\'e}ric Pinguet and Marc Ychou and Anissa Gauthey Abderrahim and Jacqueline Duffour and Françoise Bressolle},
  journal={Oncology reports},
  year={2007},
  volume={18 6},
  pages={1613-321}
}
In this study we propose for the first time a limited sampling strategy to estimate the individual pharmacokinetic parameters of both irinotecan and SN-38 in patients treated with the irinotecan plus 5-fluorouracil (FOLFIRI) regimen. The pharmacokinetics of irinotecan and SN-38 were studied in 74 patients with advanced inoperable digestive cancer. Plasma concentrations were taken during and up to the 42 h following a 90-min infusion of irinotecan (180-225 mg/m(2)). Data splitting was used to… CONTINUE READING